SGCG and PYGM

Data Source:
BioGRID (two hybrid)

		SGCG	PYGM
Description		sarcoglycan gamma	glycogen phosphorylase, muscle associated
Image		No pdb structure
GO Annotations	Cellular Component	Cytoplasm Cytoskeleton Plasma Membrane Sarcoglycan Complex Integral Component Of Membrane Sarcolemma	Cytoplasm Cytosol Extracellular Exosome
	Molecular Function	Protein Binding	Nucleotide Binding Protein Binding Glycogen Phosphorylase Activity Pyridoxal Phosphate Binding Linear Malto-oligosaccharide Phosphorylase Activity SHG Alpha-glucan Phosphorylase Activity
	Biological Process	Muscle Organ Development Cardiac Muscle Tissue Development Heart Contraction	Glycogen Metabolic Process Glycogen Catabolic Process
Pathways			Glycogen breakdown (glycogenolysis) Glycogen breakdown (glycogenolysis)
Drugs			Pyridoxal phosphate Beta-D-Glucopyranose Spirohydantoin (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione alpha-D-glucose 6-phosphate N-beta-D-glucopyranosylacetamide Monofluorophosphate ion Beta-D-Glucose 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Nojirimycine Tetrazole Indirubin-5-sulphonate 2-Deoxy-Glucose-6-Phosphate C-(1-hydrogyl-beta-D-glucopyranosyl) formamide alpha-D-glucopyranosyl-2-carboxylic acid amide alpha-D-glucose-1-phosphate 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole N-acetyl-N'-beta-D-glucopyranosyl urea 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole CP-320626 (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Alvocidib 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium N(6)-(pyridoxal phosphate)-L-lysine Heptulose-2-Phosphate N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine Dexfosfoserine 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide Inosinic Acid 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
Diseases		Sarcoglycanopathies, including: Limb-girdle muscular dystrophy (LGMD) 2C; Limb-girdle muscular dystrophy (LGMD) 2D; Limb-girdle muscular dystrophy (LGMD) 2E; Limb-girdle muscular dystrophy (LGMD) 2F Limb-girdle muscular dystrophy (LGMD)	Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
GWAS		Alanine aminotransferase levels ( 31219225) Asthma ( 27611488) Atrial fibrillation ( 30061737) Bipolar disorder ( 21738484) Central corneal thickness ( 29760442) Corneal structure ( 23291589) Number of alcoholic drinks required to feel an effect (first five times drinking) ( 31270906) Type 2 diabetes ( 23300278)	Urate levels ( 21768215)
Interacting Genes		20 interacting genes: APP CCT6A CLDN5 DNAJB6 DYSF ENO1 ENO3 FLNC HSPA1B MYBPC1 MYBPC2 MYLPF PSAP PYGM SGCB SGCD SPACA1 SSPN SUCLG2 TTN	29 interacting genes: AGTPBP1 ARID1B CDC42BPB CLASP2 DNM2 FAM110A IGBP1 INTS4 LMNA NIPSNAP2 NTAQ1 PDE4DIP POMP PPP1CA PPP1R3B PPP2CA PRKAB2 PYGB PYGL S100A1 SGCG SRP72 TOP1 TRAPPC2 TRIM54 TRIM55 TRIM63 TTN WWP1
Entrez ID		6445	5837
HPRD ID		07039	01986
Ensembl ID		ENSG00000102683	ENSG00000068976
Uniprot IDs		Q13326	P11217
PDB IDs			1Z8D
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?